Is BTMD or CLRB more profitable?

biote has a net margin of 8.29% compared to Cellectar Biosciences' net margin of 0.00%. biote's return on equity of -25.72% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets biote 8.29% -25.72% 15.12% Cellectar Biosciences N/A -349.24% -153.18%

Does the media prefer BTMD or CLRB?

In the previous week, Cellectar Biosciences had 5 more articles in the media than biote. MarketBeat recorded 9 mentions for Cellectar Biosciences and 4 mentions for biote. biote's average media sentiment score of 1.37 beat Cellectar Biosciences' score of 1.22 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TELO or CLRB?

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has preferable earnings and valuation, TELO or CLRB?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is TELO or CLRB more profitable?

Telomir Pharmaceuticals' return on equity of -201.23% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -201.23% -172.71% Cellectar Biosciences N/A -349.24% -153.18%

Does the media favor TELO or CLRB?

In the previous week, Cellectar Biosciences had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 9 mentions for Cellectar Biosciences and 2 mentions for Telomir Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 1.22 beat Telomir Pharmaceuticals' score of 0.94 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLRB or FRMM more profitable?

Forum Markets' return on equity of -242.09% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Forum Markets N/A -242.09% -135.46%

Does the media refer more to CLRB or FRMM?

In the previous week, Forum Markets had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 11 mentions for Forum Markets and 9 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.22 beat Forum Markets' score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forum Markets 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CLRB or RLYB?

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CLRB or RLYB?

In the previous week, Cellectar Biosciences had 6 more articles in the media than Rallybio. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Rallybio. Cellectar Biosciences' average media sentiment score of 1.22 beat Rallybio's score of 0.88 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, LONA or CLRB?

Athira Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is LONA or CLRB more profitable?

Cellectar Biosciences' return on equity of -349.24% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Cellectar Biosciences N/A -349.24% -153.18%

Does the media prefer LONA or CLRB?

In the previous week, Cellectar Biosciences had 6 more articles in the media than Athira Pharma. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Athira Pharma. Cellectar Biosciences' average media sentiment score of 1.22 beat Athira Pharma's score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cellectar Biosciences (CLRB) Competitors

$2.63 0.00 (0.00%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$2.74 +0.11 (+4.18%)

As of 07:05 AM Eastern

Compare

CLRB vs. BTMD, TELO, FRMM, RLYB, and LONA

Should you buy Cellectar Biosciences stock or one of its competitors? MarketBeat compares Cellectar Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectar Biosciences include biote (BTMD), Telomir Pharmaceuticals (TELO), Forum Markets (FRMM), Rallybio (RLYB), and Athira Pharma (LONA). These companies are all part of the "pharmaceutical products" industry.

How does Cellectar Biosciences compare to biote?

biote (NASDAQ:BTMD) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

21.7% of biote shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 32.4% of biote shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

biote presently has a consensus target price of $2.75, indicating a potential upside of 25.57%. Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than biote.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

biote has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$192.22M	0.43	$27.05M	$0.44	4.98
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

biote has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 5 more articles in the media than biote. MarketBeat recorded 9 mentions for Cellectar Biosciences and 4 mentions for biote. biote's average media sentiment score of 1.37 beat Cellectar Biosciences' score of 1.22 indicating that biote is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
biote	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

biote has a net margin of 8.29% compared to Cellectar Biosciences' net margin of 0.00%. biote's return on equity of -25.72% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
biote	8.29%	-25.72%	15.12%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

biote beats Cellectar Biosciences on 11 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

16.4% of Cellectar Biosciences shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Telomir Pharmaceuticals has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 7 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 9 mentions for Cellectar Biosciences and 2 mentions for Telomir Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 1.22 beat Telomir Pharmaceuticals' score of 0.94 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telomir Pharmaceuticals' return on equity of -201.23% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Summary

Cellectar Biosciences beats Telomir Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Forum Markets?

Cellectar Biosciences (NASDAQ:CLRB) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Forum Markets' return on equity of -242.09% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Forum Markets	N/A	-242.09%	-135.46%

Cellectar Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Cellectar Biosciences presently has a consensus price target of $11.00, suggesting a potential upside of 318.25%. Forum Markets has a consensus price target of $10.00, suggesting a potential upside of 47.06%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cellectar Biosciences is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Cellectar Biosciences has higher earnings, but lower revenue than Forum Markets. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Forum Markets	$9.41M	9.68	-$450.52M	-$36.07	N/A

In the previous week, Forum Markets had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 11 mentions for Forum Markets and 9 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.22 beat Forum Markets' score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 25.2% of Forum Markets shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cellectar Biosciences and Forum Markets tied by winning 7 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Rallybio?

Cellectar Biosciences (NASDAQ:CLRB) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Cellectar Biosciences had 6 more articles in the media than Rallybio. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Rallybio. Cellectar Biosciences' average media sentiment score of 1.22 beat Rallybio's score of 0.88 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market.

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cellectar Biosciences has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Rallybio	-911.07%	-55.79%	-51.48%

Rallybio has higher revenue and earnings than Cellectar Biosciences. Rallybio is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Rallybio	$860K	98.67	-$8.98M	-$4.34	N/A

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cellectar Biosciences beats Rallybio on 9 of the 16 factors compared between the two stocks.

How does Cellectar Biosciences compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Cellectar Biosciences' return on equity of -349.24% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Athira Pharma currently has a consensus price target of $15.00, indicating a potential upside of 58.98%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 318.25%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Cellectar Biosciences had 6 more articles in the media than Athira Pharma. MarketBeat recorded 9 mentions for Cellectar Biosciences and 3 mentions for Athira Pharma. Cellectar Biosciences' average media sentiment score of 1.22 beat Athira Pharma's score of 0.62 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Athira Pharma has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Athira Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Summary

Cellectar Biosciences beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.02M	$8.67B	$6.86B	$12.44B
Dividend Yield	N/A	2.55%	2.68%	8.42%
P/E Ratio	-0.39	15.65	26.96	24.38
Price / Sales	N/A	6.52	518.38	91.92
Price / Cash	N/A	18.09	48.59	59.36
Price / Book	1.39	3.56	10.90	6.33
Net Income	-$21.79M	$228.19M	$3.59B	$331.02M
7 Day Performance	-2.23%	-1.41%	-1.51%	-0.33%
1 Month Performance	12.39%	-2.08%	2.76%	-1.29%
1 Year Performance	-44.98%	2.26%	28.54%	21.30%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	4.2632 of 5 stars	$2.63 flat	$11.00 +318.3%	-47.2%	$21.02M	N/A	N/A	10	News Coverage Positive News Analyst Upgrade Short Interest Increase Analyst Revision
BTMD biote	4.6796 of 5 stars	$2.29 +0.6%	$2.75 +19.9%	-45.8%	$85.57M	$188.16M	5.18	194	News Coverage Positive News Short Interest Decrease
TELO Telomir Pharmaceuticals	0.5674 of 5 stars	$1.24 -2.4%	N/A	+6.0%	$84.94M	N/A	N/A	1
FRMM Forum Markets	3.3281 of 5 stars	$5.85 -14.1%	$10.00 +70.9%	N/A	$84.91M	$6.55M	N/A	7	News Coverage Analyst Revision
RLYB Rallybio	0.8707 of 5 stars	$15.65 -0.4%	N/A	+376.5%	$82.95M	$860K	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BTMD, TELO, FRMM, RLYB, and LONA

How does Cellectar Biosciences compare to biote?

Summary

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Summary

How does Cellectar Biosciences compare to Forum Markets?

Summary

How does Cellectar Biosciences compare to Rallybio?

Summary

How does Cellectar Biosciences compare to Athira Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BTMD, TELO, FRMM, RLYB, and LONA

How does Cellectar Biosciences compare to biote?

Do insiders & institutionals have more ownership in BTMD or CLRB?

Do analysts prefer BTMD or CLRB?

Which has higher earnings and valuation, BTMD or CLRB?

Which has more volatility and risk, BTMD or CLRB?

Does the media prefer BTMD or CLRB?

Is BTMD or CLRB more profitable?

Summary

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Do analysts recommend TELO or CLRB?

Do institutionals and insiders have more ownership in TELO or CLRB?

Which has more volatility & risk, TELO or CLRB?

Does the media favor TELO or CLRB?

Is TELO or CLRB more profitable?

Which has preferable earnings and valuation, TELO or CLRB?

Summary

How does Cellectar Biosciences compare to Forum Markets?

Is CLRB or FRMM more profitable?

Which has more risk & volatility, CLRB or FRMM?

Do analysts recommend CLRB or FRMM?

Which has higher valuation & earnings, CLRB or FRMM?

Does the media refer more to CLRB or FRMM?

Do insiders & institutionals hold more shares of CLRB or FRMM?

Summary

How does Cellectar Biosciences compare to Rallybio?

Does the media favor CLRB or RLYB?

Which has more risk & volatility, CLRB or RLYB?

Do analysts recommend CLRB or RLYB?

Is CLRB or RLYB more profitable?

Which has preferable earnings and valuation, CLRB or RLYB?

Do insiders & institutionals believe in CLRB or RLYB?

Summary

How does Cellectar Biosciences compare to Athira Pharma?

Is LONA or CLRB more profitable?

Do analysts prefer LONA or CLRB?

Does the media prefer LONA or CLRB?

Do insiders & institutionals hold more shares of LONA or CLRB?

Which has more volatility and risk, LONA or CLRB?

Which has preferable valuation and earnings, LONA or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools